The Silent Epidemic: Why Vaginal and Vulvar Cancers Deserve Our Urgent Attention
There’s a quiet crisis brewing in women’s health, one that rarely makes headlines but demands our immediate focus. Vaginal and vulvar cancers, though rare, carry survival rates that are shockingly lower than more commonly discussed cancers like breast or endometrial. What’s even more alarming? These disparities aren’t just about biology—they’re deeply rooted in systemic oversights, from diagnostic challenges to a lack of clinician familiarity.
The Numbers Don’t Lie—But They Only Tell Half the Story
Let’s start with the facts: in Australia, the five-year survival rates for vaginal and vulvar cancers are 53% and 74%, respectively. Compare that to breast cancer’s 93% or endometrial cancer’s 84%, and the gap is staggering. But here’s where it gets personal: these cancers are so rare—just 117 vaginal and 401 vulvar cases diagnosed in 2025—that many clinicians may never encounter them in their careers. This rarity breeds unfamiliarity, and unfamiliarity breeds misdiagnosis.
What many people don’t realize is that these cancers often present with vague symptoms, making them easy to overlook. Unlike breast cancer, which has mammograms, or cervical cancer, with Pap smears, there’s no standardized screening for vaginal or vulvar cancers. This isn’t just a medical oversight—it’s a societal one. We’ve normalized discussing certain cancers while leaving others in the shadows.
The Diagnostic Maze: Where Guidelines Fall Short
Here’s where things get particularly frustrating. Even when guidelines exist, they’re often outdated or incomplete. A recent systematic review identified 45 international guidelines for these cancers, but only two were from Australia—and they’re a decade old. Worse, most guidelines focus on prevention and early detection, leaving critical areas like diagnosis and referral underaddressed.
From my perspective, this highlights a broader issue: we’re treating rare cancers with a one-size-fits-all approach. Take HPV vaccination, for example. While it’s a cornerstone of prevention, it’s not enough on its own. Opportunistic screening during cervical exams can catch precursors, but only if clinicians know what to look for. And let’s be honest—how many general practitioners are trained to recognize the subtle signs of vaginal or vulvar cancer?
The Missing Piece: Patient Voices and Cultural Sensitivity
One thing that immediately stands out is the absence of patient perspectives in these guidelines. Few incorporate the experiences of those most affected, particularly marginalized groups like Aboriginal and Torres Strait Islander women, rural populations, or older Australians. This isn’t just a moral failing—it’s a practical one. Guidelines that don’t account for cultural or logistical barriers are doomed to fail in real-world settings.
If you take a step back and think about it, this is a symptom of a larger problem in healthcare: we’re designing solutions without the people they’re meant to serve. What this really suggests is that we need to rethink how guidelines are developed. Including patient voices isn’t just a nice-to-have—it’s essential for creating pathways that are equitable, accessible, and effective.
The Path Forward: Optimal Care Pathways and Beyond
Here’s where there’s a glimmer of hope: Optimal Care Pathways (OCPs). These standardized frameworks have proven effective for cancers like colorectal, but they’re still missing for vaginal and vulvar cancers. An OCP could bridge the gaps in current guidelines by providing clear, actionable steps for clinicians while addressing the unique needs of underserved populations.
But let’s be clear—developing an OCP isn’t enough. We need to evaluate existing screening practices, particularly as self-collection for HPV testing becomes more common. While it’s a game-changer for accessibility, it reduces opportunities for physical exams that might catch HPV-independent cases. This raises a deeper question: are we sacrificing comprehensive care for convenience?
A Call to Action: Why This Matters to All of Us
Personally, I think the conversation around vaginal and vulvar cancers is long overdue. These aren’t just medical conditions—they’re reflections of how we prioritize women’s health. The fact that they’re rare doesn’t make them any less devastating for those affected.
What makes this particularly fascinating is how it intersects with broader trends in healthcare. We’re quick to celebrate advancements in high-profile cancers but slow to address disparities in less visible ones. If we’re serious about equity, we need to start with the cancers that are easiest to ignore.
Final Thoughts: The Power of Awareness
In my opinion, the first step to change is awareness. We need to talk about these cancers openly, educate clinicians rigorously, and involve patients in shaping the solutions. It’s not just about improving survival rates—it’s about recognizing the dignity and worth of every woman affected.
If we can do that, we’re not just addressing a medical gap—we’re redefining what it means to care. And that, to me, is the most important takeaway of all.
